NAMS Stock Forecast & Price Target

NewAmsterdam Pharma Co is viewed positively because obicetrapib has repeatedly shown meaningful LDL-C lowering in multiple ph.I and ph.II studies, a clean safety profile, and convenient once-daily oral dosing that could address the limitations of statins and injectable PCSK9s. The investment case is further strengthened by a large unmet need, with as many as 50% of U.S. patients not reaching cholesterol goals and 9-15% unable to tolerate statins, supporting a potentially substantial oral switch or add-on market. Despite interim PREVAIL risk, the company’s 9,500-patient outcomes trial and the prospect of roughly 20% MACE reduction, alongside estimated WW sales of $3.1B to $3.5B+, underpin a favorable long-term fundamental outlook.

NewAmsterdam Pharma Co is viewed negatively because its valuation hinges almost entirely on PREVAIL, yet the interim analysis is now being pulled forward to 4Q26 after a slower-than-expected event rate, which itself signals execution risk rather than strength. The analysis suggests the MACE-3 endpoint is the binding constraint, with only about a 35-38% chance of success at the interim versus MACE-4’s much higher probability, and even the more detailed model implies roughly a 25-40% overall chance after about 400 MACE-3 events. Compounding that risk, prior CETP inhibitors have failed, the market may not translate LDL reductions into meaningful MACE benefit, the company has no revenues, and its composition-of-matter patent expires in 2027, limiting long-term exclusivity.